Development and in vitro safety evaluation of pramipexole-loaded hollow mesoporous silica (HMS) particles

References

• Weiner WJ, Factor SA, Jankovic J, et al. The long-term safety and efficacy of pramipexole in advanced Parkinson’s disease. Parkinsonism Relat Disord. 2001;7:115–120.
   PubMed Web of Science ®Google Scholar
• Moller JC, Oertel WH, Koster J, et al. Long-term efficacy and safety of pramipexole in advanced Parkinson’s disease: results from a European multicenter trial. Mov Disord. 2005;20:602–610.
   PubMed Web of Science ®Google Scholar
• Kreiss DS, Bergstrom DA, Gonzalez AM, et al. Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities. Eur J Pharmacol. 1995;277:209–214.
   PubMed Web of Science ®Google Scholar
• Danzeisen R, Schwalenstoecker B, Gillardon F, et al. Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride]. J Pharmacol Exp Ther. 2006;316:189–199.
   PubMed Web of Science ®Google Scholar
• Kitamura Y, Kosaka T, Kakimura JI, et al. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol Pharmacol. 1998;54:1046–1054.
   PubMed Web of Science ®Google Scholar
• Gu M, Iravani MM, Cooper JM, et al. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J Neurochem. 2004;91:1075–1081.
   PubMed Web of Science ®Google Scholar
• Abramova NA, Cassarino DS, Khan SM, et al. Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma. J Neurosci Res. 2002;67:494–500.
   PubMed Web of Science ®Google Scholar
• Ferrari-Toninelli G, Maccarinelli G, Uberti D, et al. Mitochondria-targeted antioxidant effects of S (-) and R (+) pramipexole. BMC Pharmacol. 2010;10:2.
   PubMedGoogle Scholar
• Pellicano C, Benincasa D, Fanciulli A, et al. The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson’s disease: an observational study. Eur J Med Res. 2013;18:60.
   PubMed Web of Science ®Google Scholar
• Schapira AH, Barone P, Hauser R, et al. Efficacy and safety of pramipexole extended-release for advanced Parkinson’s disease [Abstract]. Mov Disord. 2009;24:277.
   PubMed Web of Science ®Google Scholar
• Linazasoro G, Nanotechnologies for Neurodegenerative Diseases Study Group of the Basque Country (NANEDIS). Potential applications of nanotechnologies to Parkinson’s disease therapy. Parkinsonism Relat Disord. 2008;14:383–392.
   PubMed Web of Science ®Google Scholar
• Beck JS, Vartuli JC, Roth WJ, et al. A new family of mesoporous molecular sieves prepared with liquid crystal templates. J Am Chem Soc.. 1992;114:10834–10843.
   Web of Science ®Google Scholar
• Yang XY, Zhang SB, Qiu ZM, et al. Stable ordered mesoporous silica materials templated by high-temperature stable surfactant micelle in alkaline media. J Phys Chem B. 2004;108:4696–4700.
   Web of Science ®Google Scholar
• Jiang T, Shen W, Tang Y, et al. Stability and characterization of mesoporous molecular sieve using natural clay as a raw material obtained by microwave irradiation. Appl Surf Sci. 2008;254:4797–4805.
   Web of Science ®Google Scholar
• Yoncheva K, Tzankov B, Popova M, et al. Evaluation of stability of mesoporous silica nanoparticles and their further formulation in tablet form. J Dispers Sci Technol. 2016;37:113–118.
   Web of Science ®Google Scholar
• Song K, Guan J, Wang Z, et al. Post-treatment of mesoporous material with high temperature for synthesis super-microporous materials with enhanced hydrothermal stability. Appl Surf Sci. 2009;255:5843–5846.
   Web of Science ®Google Scholar
• Wang Y, Zhao Q, Han N, et al. Mesoporous silica nanoparticles in drug delivery and biomedical applications. Nanomedicine. 2015;11:313–327.
   PubMed Web of Science ®Google Scholar
• Niedermayer S, Weiss V, Herrmann A, et al. Multifunctional polymer-capped mesoporous silica nanoparticles for pH-responsive targeted drug delivery. Nanoscale. 2015;7:7953–7964.
   PubMed Web of Science ®Google Scholar
• Yao XM, Chen XF, He CL, et al. Dual pH-responsive mesoporous silica nanoparticles for efficient combination of chemotherapy and photodynamic therapy. J Mater Chem B. 2015;3:4707–4714.
   PubMed Web of Science ®Google Scholar
• Li ZY, Hu JJ, Xu Q, et al. A redox-responsive drug delivery system based on RGD containing peptide-capped mesoporous silica nanoparticles. J Mater Chem B. 2015;3:39–44.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang B, Luo Z, et al. Enzyme responsive mesoporous silica nanoparticles for targeted tumor therapy in vitro and in vivo. Nanoscale. 2015;7:3614–3626.
   PubMed Web of Science ®Google Scholar
• Baek S, Singh RK, Khanal D, et al. Smart multifunctional drug delivery towards anticancer therapy harmonized in mesoporous nanoparticles. Nanoscale. 2015;7:14191–14216.
   PubMed Web of Science ®Google Scholar
• Tang S, Huang X, Chen X, et al. Hollow mesoporous zirconia nanocapsules for drug delivery. Adv Funct Mater. 2010;20:2442–2447.
   Web of Science ®Google Scholar
• Yeo KM, Choi S, Anisur RM, et al. Surfactant‐free platinum‐on‐gold nanodendrites with enhanced catalytic performance for oxygen reduction. Angew Chem Int Ed. 2011;50:745–748.
   PubMed Web of Science ®Google Scholar
• Liu S, Yu J, Jaroniec M. Tunable photocatalytic selectivity of hollow TiO2 microspheres composed of anatase polyhedra with exposed {001} facets. J Am Chem Soc. 2010;132:11914–11916.
   PubMed Web of Science ®Google Scholar
• Caruso F, Caruso RA, Möhwald H. Nanoengineering of inorganic and hybrid hollow spheres by colloidal templating. Science. 1998;282:1111–1114.
   PubMed Web of Science ®Google Scholar
• Sun Y, Mayers B, Xia Y. Metal nanostructures with hollow interiors. Adv Mater. 2003;15:641–646.
   Web of Science ®Google Scholar
• An K, Hyeon T. Synthesis and biomedical applications of hollow nanostructures. Nano Today. 2009;4:359–373.
   Web of Science ®Google Scholar
• Hu J, Chen M, Fang X, et al. Fabrication and application of inorganic hollow spheres. Chem Soc Rev. 2011;40:5472–5491.
   PubMed Web of Science ®Google Scholar
• Li L, Tang F, Liu H, et al. In vivo delivery of silica nanorattle encapsulated docetaxel for liver cancer therapy with low toxicity and high efficacy. ACS nano. 2010;4:6874–6882.
   PubMed Web of Science ®Google Scholar
• Nejabat M, Mohammadi M, Abnous K, et al. Fabrication of acetylated carboxymethylcellulose coated hollow mesoporous silica hybrid nanoparticles for nucleolin targeted delivery to colon adenocarcinoma. Carbohydr Polym. 2018;197:157–166.
   PubMed Web of Science ®Google Scholar
• Fang J, Liu Y, Chen Y, et al. Graphene quantum dots-gated hollow mesoporous carbon nanoplatform for targeting drug delivery and synergistic chemo-photothermal therapy. IJN. 2018;Volume 13:5991. [cited 2019 May 28]
   Google Scholar
• Moghaddam SPH, Yazdimamaghani M, Ghandehari H. Glutathione-sensitive hollow mesoporous silica nanoparticles for controlled drug delivery. J Control Release. 2018;282:62–75.
   PubMed Web of Science ®Google Scholar
• Jia X, Yang Z, Wang Y, et al. Hollow mesoporous silica metal-organic framework and applications for pH‐responsive drug delivery. Chem Med Chem. 2018;13:400–405.
   Google Scholar
• Huang L, Liu J, Gao F, et al. A dual-responsive, hyaluronic acid targeted drug delivery system based on hollow mesoporous silica nanoparticles for cancer therapy. J Mater Chem B. 2018;6:4618–4629.
   PubMed Web of Science ®Google Scholar
• Park SS, Ha CS. Hollow mesoporous functional hybrid materials: fascinating platforms for advanced applications. Adv Funct Mater. 2018;28:1703814.
   Web of Science ®Google Scholar
• Yang Q, Li L, Zhao F, et al. Hollow silica–polyelectrolyte composite nanoparticles for controlled drug delivery. J Mater Sci. 2019;54:2552–2565.
   Web of Science ®Google Scholar
• Teng Z, Li W, Tang Y, et al. Mesoporous organosilica hollow nanoparticles: synthesis and applications. Adv Mater. 2018;2018:1707612.
   Google Scholar
• Chen Y, Chu C, Zhou Y, et al. Reversible pore‐structure evolution in hollow silica nanocapsules: large pores for siRNA delivery and nanoparticle collecting. Small. 2011;7:2935–2944.
   PubMed Web of Science ®Google Scholar
• Gao F, Li L, Liu T, et al. Doxorubicin loaded silica nanorattles actively seek tumors with improved anti-tumor effects. Nanoscale. 2012;4:3365–3372.
   PubMed Web of Science ®Google Scholar
• Zhu YF, Shi JL, Li YS, et al. Storage and release of ibuprofen drug molecules in hollow mesoporous silica spheres with modified pore surface. Microporous Mesoporous Mater. 2005;85:75–81.
   Web of Science ®Google Scholar
• Zhu Y, Shi J, Shen W, et al. Preparation of novel hollow mesoporous silica spheres and their sustained-release property. Nanotechnology 2005;16:2633.
   Web of Science ®Google Scholar
• Gombotz WR, Wee S. Protein release from alginate matrices. Adv Drug Deliv Rev. 1998;31:267–285.
   PubMed Web of Science ®Google Scholar
• McNeely WH, Kang KS. Xanthan and some other biosynthetic gums. Indus Gums. 1973;2:473–497.
   Google Scholar
• Lee DW, Lim C, Israelachvili JN, et al. Strong adhesion and cohesion of chitosan in aqueous solutions. Langmuir 2013;29:14222–14229.
   PubMed Web of Science ®Google Scholar
• Lim C, Lee DW, Israelachvili JN, et al. Contact time- and pH-dependent adhesion and cohesion of low molecular weight chitosan coated surfaces. Carbohydr Polym. 2015;117:887–894.
   PubMed Web of Science ®Google Scholar
• Suddhasattya D, Prasanna KP, Upadhayay UM, et al. Method development and validation of pramipexole by UV spectrophotometric method. J Pharm Res. 2012;5:5052–5054.
   Google Scholar
• Evans BC, Nelson CE, Shann S, et al. Ex vivo red blood cell hemolysis assay for the evaluation of pH-responsive endosomolytic agents for cytosolic delivery of biomacromolecular drugs. J Vis Exp. 2013;2013:e50166.
   Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Method. 1983;65:55–63.
   PubMed Web of Science ®Google Scholar
• Sing KSW, Everett DH, Haul RHW, et al. International union of pure and applied chemistry physical chemistry division reporting physisorption data for gas/soils systems with special reference to the determination of surface area and porosity. Pure Appl Chem. 1985;57:603–619.
   Web of Science ®Google Scholar
• Venkateswarlu K, Thakur H, Babu TNB. Fabrication of extended release tablets of pramipexole: in-vitro studies. Pharm Methods. 2017;8:115–120.
   Google Scholar
• Romero AA, Alba MD, Zhou W, et al. Synthesis and characterization of the mesoporous silicate molecular sieve MCM-48. J Phys Chem B. 1997;101:5294–5300.
   Web of Science ®Google Scholar
• Takahashi R, Sato S, Sodesawa T, et al. High surface-area silica with controlled pore size prepared from nanocomposite of silica and citric acid. J Phys Chem B. 2000;104:12184–12191.
   Web of Science ®Google Scholar
• Sartori C, Finch DS, Ralph B, et al. Determination of the cation content of alginate thin films by FTIR spectroscopy. Polymer 1997;38:43–51.
   Web of Science ®Google Scholar
• Omwancha WS, Mallipeddi R, Valle BL, et al. Chitosan as a pore former in coated beads for colon specific drug delivery of 5-ASA. Int J Pharm. 2013;441:343–351.
   PubMed Web of Science ®Google Scholar
• Lee JE, Lee N, Kim T, et al. Multifunctional mesoporous silica nanocomposite nanoparticles for theranostic applications. Acc Chem Res. 2011;44:893–902.
   PubMed Web of Science ®Google Scholar
• Godin B, Gu J, Serda RE, et al. Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation. J Biomed Mater Res. 2010;94:1236–1243.
   Google Scholar
• Jaganathan H, Godin B. Biocompatibility assessment of Si-based nano-and micro-particles. Adv Drug Deliv Rev. 2012;64:1800–1819.
   PubMed Web of Science ®Google Scholar
• Aluani D, Tzankova V, Kondeva-Burdina M, et al. еvaluation of biocompatibility and antioxidant efficiency of chitosan-alginate nanoparticles loaded with quercetin. Int J Biol Macromol. 2017;103:771–782.
   PubMed Web of Science ®Google Scholar
• Xu M, Feng C, Wang J, et al. In vitro heterogeneous degradation of alginate and its validation of different molecular weight on blood bio-compatibility. J Biomater Sci Polym Ed. 2017;28:380–393.
   PubMed Web of Science ®Google Scholar
• Cassarino DS, Fall CP, Smith TS, et al. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem. 2002;71:295–301.
   Google Scholar
• Lu F, Wu SH, Hung Y, et al. Size effect on cell uptake in well-suspended, uniform mesoporous silica nanoparticles. Small. 2009;5:1408–1413.
   PubMed Web of Science ®Google Scholar
• Mai Z, Chen J, Hu Y, et al. Novel functional mesoporous silica nanoparticles loaded with Vitamin E acetate as smart platforms for pH responsive delivery with high bioactivity. J Colloid Interface Sci. 2017;508:184–195.
   PubMed Web of Science ®Google Scholar
• Ambati J, Lopez AM, Cochran D, et al. Engineered silica nanocarriers as a high-payload delivery vehicle for antioxidant enzymes. Acta Biomater. 2012;8:2096–2103.
   PubMed Web of Science ®Google Scholar
• Raj R, Wairkar S, Sridhar V, et al. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: development, characterization and in vivo anti-Parkinson activity. Int J Biol Macromol. 2018;109:27–35.
   PubMed Web of Science ®Google Scholar